Ellis D L
Department of Medicine, Vanderbilt University, Nashville, TN.
J Am Acad Dermatol. 1991 Sep;25(3):467-82. doi: 10.1016/0190-9622(91)70227-s.
Female patients with the dysplastic nevus syndrome who were pregnant or taking sex steroid hormones were prospectively studied to evaluate the effectiveness of photography and close clinical follow-up in detecting nevus change or melanoma development. Seventeen patients, who served as their own controls, were studied during 22 pregnancies. Twenty-four patients who used oral contraceptives and seven who took hormone supplements were similarly studied. This clinical management method provided timely biopsy of changing nevi with a small number of biopsies required per patient. One melanoma occurred during pregnancy, but neither patients who were taking sex steroid hormones nor those in the control groups had melanomas. The rate of nevus change observed clinically was 3.9 times higher when patients with dysplastic nevus syndrome were pregnant than when they were not, whereas no differences were observed whether or not women took oral contraceptives or hormone supplements. The rate of histologically proven dysplastic nevi that changed was 2.0-fold higher when women were pregnant; 1.4-fold higher with the use of hormone supplements and 1.1-fold higher with the use of oral contraceptives. These preliminary data suggest pregnancy and hormone supplements may be temporally associated with an increased rate of dysplastic nevus change.
对患有发育异常痣综合征的妊娠女性或正在服用性甾体激素的女性患者进行前瞻性研究,以评估摄影和密切临床随访在检测痣变化或黑色素瘤发生方面的有效性。17名患者在22次妊娠期间接受研究,这些患者以自身作为对照。对24名使用口服避孕药的患者和7名服用激素补充剂的患者进行了类似研究。这种临床管理方法能够及时对变化的痣进行活检,每位患者所需的活检次数较少。妊娠期间发生了1例黑色素瘤,但服用性甾体激素的患者和对照组患者均未发生黑色素瘤。发育异常痣综合征患者妊娠时临床观察到的痣变化率比未妊娠时高3.9倍,而女性是否服用口服避孕药或激素补充剂则未观察到差异。组织学证实发生变化的发育异常痣发生率在女性妊娠时高2.0倍;服用激素补充剂时高1.4倍,服用口服避孕药时高1.1倍。这些初步数据表明,妊娠和激素补充剂可能在时间上与发育异常痣变化率增加有关。